
Naoto T. Ueno: No Difference in pCR, but Better Disease Control With Anthracyclines in HER2+ IBC
Naoto T. Ueno, Director at University of Hawai’i Cancer Center, shared on X about a recent paper by Toshiaki Iwase et al. published on Springer Nature:
“A study finds no difference in pCR between regimens with or without anthracyclines in HER2-positive inflammatory breast cancer (IBC). But those on anthracyclines had better disease control. More research needed!”
Title: Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study
Authors: Toshiaki Iwase, Nithya Sridhar, Megumi Kai, Wenli Dong, Yu Shen, Savitri Krishnamurthy, Anthony Lucci, H. T. Carisa Le-Petross, Azadeh Nasrazadani, Sadia Saleem, Rachel M. Layman, Vincente Valero, Debasish Tripathy, Wendy A. Woodward, Yee Chung Cheng, Faina Nakhlis, Jenifer R. Bellon, Filipa Lynce & Naoto T. Ueno
More posts featuring Inflammatory Breast Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023